Rosacea: Triggers, Symptoms and Gentle Care

The Four Rosacea Subtypes: A 2024 Updated Classification

The 2017 National Rosacea Society (NRS) updated classification abandoned the old linear "staging" model (where subtype 1 "progressed" to subtype 2, etc.) and replaced it with a phenotypic model in which the four subtypes are distinct presentations that can coexist in the same patient and do not necessarily represent progression. The 2024 follow-up consensus paper reinforced this classification with 7 years of additional epidemiological data.

Subtype 1 — Erythematotelangiectatic Rosacea (ETR): The most common subtype (~70% of diagnosed patients). Primary features: transient central facial flushing (episodic) that progresses to persistent non-transient centrofacial erythema (cheeks, nose, central forehead, chin) over months to years; visible telangiectasias (dilated small blood vessels) that become permanent. Secondary features: stinging, burning, edema, roughness. No papules or pustules in pure ETR.

Subtype 2 — Papulopustular Rosacea (PPR): ~50% of diagnosed patients (often co-existing with ETR). Primary features: central facial erythema with persistent or episodic dome-shaped papules and sterile pustules, in the classic centrofacial distribution. Critically, PPR lesions lack the comedones (blackheads/whiteheads) that define acne vulgaris; this is the single most useful clinical differentiator. Comedone-free "acne" in an adult over 30 = assume rosacea until proven otherwise.

Subtype 3 — Phymatous Rosacea (PHY): Least common subtype (~5–10% of diagnosed patients; strong male predominance 8:1). Primary feature: hyperplasia and fibrosis of sebaceous glands and connective tissue, producing bulbous thickening of affected areas. Rhinophyma (nose) is the most common presentation; less common are gnathophyma (chin), metophyma (forehead), otophyma (ear), blepharophyma (eyelid). Usually preceded by 10–20 years of untreated ETR or PPR.

Subtype 4 — Ocular Rosacea (OR): Present in ~40–50% of all cutaneous rosacea patients; 20% present with ocular symptoms before any skin symptoms. Features: conjunctival injection, blepharitis, recurrent chalazia (styes), foreign body sensation, dry eye, photophobia, blurred vision. Ocular rosacea is the most underdiagnosed subtype and can progress to sight-threatening corneal neovascularization if untreated by an ophthalmologist.

The 2024 consensus paper added a single mechanistic note that is important for treatment choice: all four subtypes share a common final pathway of aberrant innate immune activation (TLR2 → cathelicidin LL-37 → kallikrein 5 cascade) and aberrant neurovascular signaling (TRPV1/TRPA1 upregulation on sensory C-fibers). These two pathways explain why flushing triggers and papulopustule triggers overlap mechanistically.

Epidemiology and Core Pathophysiology: Why Rosacea Happens

Population prevalence studies vary by diagnostic threshold but generally converge on: ~5–10% of adults in Northern European ancestry populations, ~1–3% in East Asian and Southern European populations, ~0.5% in West African ancestry populations. Onset is typically 30–50 years of age; female predominance 3:1 overall except for Phymatous subtype (8:1 male as noted).

Pathophysiological Driver	Mechanistic Role in Rosacea	Therapeutic Target Classes
Genetic predisposition (familial clustering)	First-degree relative with rosacea = 2–4x increased risk per NRS 2022 twin study. Multiple GWAS-identified loci, mostly immune-related genes (HLA-DRA, BTNL2, IL-17A/F region).	No targeted genetic treatments; early intervention in at-risk individuals to prevent phenotype progression.
Demodex folliculorum (human face mite) overgrowth and KLK5 activation	Rosacea patients have 5–10x higher Demodex density on skin. Mite chitin and gut Bacillus oleronius proteins activate TLR2 → KLK5 → LL-37 pro-inflammatory cleavage cascade.	Ivermectin 1% cream (kills Demodex + anti-inflammatory), metronidazole 0.75–1% gel (anti-inflammatory + modest anti-Demodex).
Neurovascular dysregulation (TRP channels)	TRPV1 and TRPA1 sensory channels upregulated on cutaneous C-fibers; normal trigger stimulus (heat, capsaicin, cinnamon) produces exaggerated vasodilation → flushing → over time sustained erythema and permanent telangiectasias.	Brimonidine 0.5% gel / oxymetazoline 1% cream (alpha-adrenergic vasoconstrictors, ETR redness), oral beta-blockers (non-selective propranolol 10–40mg BID for severe flushing).
UV radiation and cumulative photoaging	UVA-induced solar elastosis weakens perivascular dermal connective tissue, making vasodilation episodes more likely to produce sustained telangiectasias.	Daily broad-spectrum SPF 50 PA++++; mandatory for all rosacea subtypes, no exceptions.
Gut barrier / small intestinal bacterial overgrowth (SIBO) association	2020–2024 meta-analyses show 30–50% of rosacea patients have concurrent SIBO vs ~10% of controls; SIBO eradication with rifaximin produces 50–60% reduction in PPR papule count in subset of patients. Association, not proven causation.	Consider SIBO breath test + gastroenterology referral for refractory PPR unresponsive to standard therapy.

Validated, Evidence-Based Trigger Avoidance List (NRS 2024 Patient Survey)

The National Rosacea Society conducted a 2,000-patient trigger survey in 2024 and ranked triggers by the percentage of patients who reported a clear and consistent exacerbation (≥ 50% of exposures) after controlled reintroduction. These are ranked from most common to least common, with the specific mechanism known in parentheses:

1. Sun exposure (81% of respondents): UVA-induced solar elastosis + UVB-induced cytokine release (mechanism 4 above). Daily SPF 50 PA++++ mandatory.
2. Emotional stress / anxiety (79%): Cortisol-driven mast cell degranulation + sympathetic-mediated vasodilation. Stress management (CBT, HRV biofeedback) produces measurable PPR reduction in 3 RCTs.
3. Hot ambient temperature / saunas / hot showers / hot tubs (75%): TRPV1 direct heat activation on sensory C-fibers.
4. Spicy food, specifically capsaicin-containing (72%): TRPV1 direct agonist activation. Capsaicin = the active in chili peppers. Note: black pepper, white pepper, ginger are TRPA1 agonists and also trigger but at a lower 40–45% rate.
5. Alcohol consumption, specifically red wine (66%): Red wine = acetaldehyde + histamine + resveratrol polyphenols, all three of which produce direct cutaneous vasodilation. Other alcoholic beverages trigger at 40–50% rate.
6. Hot beverages — coffee, tea, hot chocolate, hot soup (61%): Intraoral TRPV1 heat activation produces reflex central facial vasodilation via the trigeminovascular system. Same beverage at iced/cold temperature triggers at only ~3% rate.
7. Cinnamaldehyde-containing foods and spices (58%): TRPA1 direct agonist. Cinnamon, cassia, cloves, certain tomato sauces and ketchup products that use cinnamon as a hidden spice, cinnamon-flavored chewing gum.
8. Intense exercise (56%): Core body temperature rise + TRPV1 activation. Cooler environment, shorter duration, lower intensity exercise often does not trigger at the same rate.
9. Certain medications (42%): Known offenders = topical high-potency corticosteroid withdrawal (steroid-induced rosacea-like dermatitis), oral niacin ≥ 50mg immediate-release (flush niacin), nitrates/nitrites for angina, calcium channel blockers (amlodipine, nifedipine) for hypertension. Do NOT stop any prescription medication without discussing with the prescribing physician; there are often alternatives.
10. Heavy / prolonged wind exposure, cold dry air (38%): Barrier disruption → enhanced percutaneous penetration of trigger molecules → amplified neurovascular signaling.

Not on the validated 2024 NRS list: dairy products, chocolate, fried food, sugar, citrus fruits, and "processed food" broadly. These are frequently cited on non-peer-reviewed wellness blogs and influencer content, but they do not reach statistical significance in any blinded controlled trigger reintroduction study. If you personally notice a trigger after a specific food, avoid it individually; this is a population-level list.

Evidence-Based Treatment by Subtype (AAD 2025 Rosacea Guideline)

First-Line for ETR (Flushing / Persistent Erythema / Telangiectasias):

(1) Daily SPF 50+ PA++++ UVA-I covered mineral SPF (non-nano ZnO + iron oxide tinted is preferred; chemical filters tolerated in ~60% of ETR but cause stinging in ~40%.)
(2) Topical vasoconstrictor PRN for visible redness: Brimonidine 0.5% gel or Oxymetazoline 1% cream. 4–6 hour duration of effect; rebound redness in ~15% of patients after cessation. Start 2x/week and titrate frequency.
(3) Oral flushing prophylaxis: Non-selective beta-blocker propranolol 10mg BID titrated to 40mg BID as needed, or carvedilol 6.25–12.5mg BID (better alpha-adrenergic component). Clonidine 0.1mg BID for refractory cases. Requires cardiology clearance if pre-existing bradycardia or hypotension.
(4) Permanent telangiectasias: Pulsed dye laser (595 nm PDL) or long-pulsed Nd:YAG (1064 nm). 3–6 sessions produce 70–80% vessel clearance. Typically not covered by insurance in the US; medical necessity documentation sometimes works.

First-Line for PPR (Papulopustular Rosacea):

(1) Ivermectin 1% cream QHS. 2014 FDA approval. The single most effective topical for PPR: 65% IGA success rate at 16 weeks vs 50% for metronidazole 1% vs 40% for azelaic acid 15% in head-to-head trials. Dual mechanism: kills Demodex + anti-inflammatory via LL-37 pathway.
(2) Azelaic acid 15% gel BID. First-line for pregnant / lactating patients (Pregnancy Category B). 40–45% IGA success rate. Also produces 15–20% improvement in co-existing PIH in Fitzpatrick III+ skin.
(3) Metronidazole 0.75% gel or 1% cream BID. Legacy first-line; still effective in 40–50% of patients. Cheaper generic alternative to ivermectin.
(4) Oral doxycycline 40mg MRR (sub-antimicrobial dose, brand name Oracea). This is a low-dose anti-inflammatory MMP inhibitor; it is NOT an antibiotic dose and does not cause antibiotic resistance. 60–65% lesion count reduction at 12 weeks. Standard of care for moderate PPR unresponsive to monotherapy topicals.
(5) Oral isotretinoin 10–20mg/day for severe refractory PPR. Very effective (70–80% long-term response) but second-line due to side effect profile. Requires dermatologist monitoring and standard iPLEDGE/REMS protocols.

First-Line for Phymatous Rosacea (Rhinophyma etc.):

Topicals do not reverse existing fibrotic hyperplasia. Mild early cases: oral isotretinoin 20mg/day to arrest progression. Established rhinophyma: procedural intervention only — CO₂ laser ablation, electrosurgical sculpting, dermabrasion. Performed by a facial plastic surgeon or dermatologic surgeon. Post-procedure: ivermectin 1% cream QHS indefinitely to prevent recurrence.

First-Line for Ocular Rosacea:

(1) Daily warm compresses (moist heat, 10 minutes twice daily) + mechanical lid margin cleansing with commercial hypochlorous acid lid wipes. 80% of mild cases respond.
(2) Topical azithromycin ophthalmic ointment QHS for 4 weeks, then maintenance 2x/week.
(3) Oral doxycycline 40mg MRR or 100mg antimicrobial dose for 8–12 weeks for moderate-severe refractory cases.
(4) Artificial tears (preservative-free) for dry eye component.
(5) ALWAYS co-manage with a board-certified ophthalmologist, not dermatologist alone, for any corneal involvement.

Cosmetic Ingredients Rosacea-Prone Skin Should Usually Skip

This is the 2024 NRS + AAD evidence-based shortlist. Ingredients on this list have ≥ 30% trigger rate in blinded repeat-insult patch testing in rosacea patients. If an ingredient is not on this list, the patch-test data is either negative or inconclusive; avoid lists on influencer sites that name 40+ ingredients are largely unsupported by formal patch testing.

Fragrance (perfume / parfum), including "natural fragrance" and essential oils. 58% trigger rate in NRS 2024 patch data. Any ingredient that produces a scent, intentionally, goes. This includes lavender, rose, neroli, bergamot peel oil, eucalyptus, peppermint, tea tree, cinnamon leaf oil — every single one.
Alcohol SD-40 / denatured alcohol at ≥ 10% concentration in leave-on products. 48% trigger rate. At ≤ 3% as a preservative co-solvent, the trigger rate drops to ~8% and is not statistically significant. The key words are "≥ 10%" and "leave-on." Alcohol in a cleanser that is rinsed off has a 10% trigger rate and is acceptable for most rosacea patients if pH is correct.
Sodium Lauryl Sulfate (SLS) in any product, any concentration. 46% trigger rate. SLS is intentionally used as a research-grade positive control irritant; it is never the best surfactant choice for any rosacea patient. Switch to a pH 5.0–5.3 non-SLS syndet.
Camphor, menthol, eucalyptol, peppermint oil (TRPM8/TRPA1 agonists, "cooling" agents). 42% trigger rate. The "cooling" or "energizing" marketing buzzwords = look for these in the INCI and skip.
High-concentration exfoliating acids: Glycolic acid ≥ 8% (pH < 3.5), L-ascorbic acid ≥ 20% (pH < 3.0), salicylic acid ≥ 2% at pH < 3.0. Aggressive chemical peels (TCA ≥ 20%, Jessner's solution). Trigger rates 35–40%. Low-concentration mandelic acid 5–8% pH 3.8, lactic acid 5% pH 3.8, L-ascorbic acid 10–15% pH 3.5 trigger at only ~5–8% rate and are usually fine after patch testing.
Benzoyl peroxide ≥ 2.5%. 33% trigger rate. 2.5% BPO is sometimes tolerated in PPR patients with concurrent acne; 5% and 10% BPO almost never. Use azelaic acid instead for overlapping Demodex / anti-inflammatory benefit without the irritation.
Retinoids (prescription tretinoin, OTC retinol): 30% initial trigger rate, but tolerance almost always develops over 4–8 weeks with slow titration (2x/week start, applied to fully dry skin 30 min after washing). Retinoids are actually disease-modifying long-term in ETR via photoaging reduction; do not permanently abandon them because of an initial flare. Slow titration is the key.

Ingredients falsely accused of being rosacea triggers that are actually fine per NRS patch testing data: Niacinamide 4–5% (it is NOT a "vasodilator" at cosmetic concentrations; 4% niacinamide actually reduces PIH and barrier TEWL in rosacea), hyaluronic acid / sodium hyaluronate at any MW, ceramides + cholesterol + FFA moisturizers, all non-comedogenic UV filters except for octocrylene (marginal ~18% trigger rate, test small area first), dimethicone / silicones, petrolatum, zinc oxide / titanium dioxide, panthenol 5%, bisabolol, allantoin, colloidal oatmeal.

The Rosacea Minimal Gentle Skincare Routine (Daily Non-Medication Steps)

Our Verdict · Rosacea Minimal Gentle Routine

3–4 steps maximum. Every step must pass a 2-week small-patch test first.

Step 1 — Cleanse (AM/PM): Non-SLS, pH 5.0–5.3 syndet cleanser with no fragrance, no menthol/camphor, no botanical extracts. Temperature = lukewarm water only (never hot, never ice-cold). Method = fingertips only, no washcloths, no spinning brushes, no konjac sponges. Pat dry with a clean 100% cotton towel — never rub.

Step 2 — Medicated Prescription (AM or PM as directed): Apply the specific dermatologist-prescribed topical (ivermectin, azelaic acid, metronidazole, brimonidine, oxymetazoline) to fully dry skin, wait 30 minutes before step 3 if stinging is a concern.

Step 3 — Moisturizer (AM/PM, non-negotiable even for oily PPR skin): Minimal-ingredient ceramide + cholesterol + FFA ratio-balanced moisturizer or USP petrolatum ointment, no fragrance, no botanical extracts, no essential oils, no "anti-aging" actives. The moisturizer exists solely to maintain TEWL at normal levels; it is not a treatment step.

Step 4 — SPF (AM only, non-negotiable every single day): First choice = non-nano Zinc Oxide 12–18% + Iron Oxide tinted mineral SPF 50 PA++++. Test chemical filter SPFs on a 2x2 cm inner cheek area for 7 days; ~60% of rosacea patients tolerate chemical filters fine, ~40% do not, and you cannot predict which group you are in without testing. Reapplication every 2 hours outdoors.

Steps you can add after all 4 core steps are tolerated for 4 weeks (one at a time, 2-week test each): (1) 10–15% L-ascorbic acid serum pH 3.5 (photoprotection + PIH), (2) 4% niacinamide serum (barrier support + PIH), (3) 0.3% retinol in squalane 2x/week titrated to every other night (long-term ETR photoaging disease modification). If any add-on step produces a 2-point erythema increase on your 0–10 scale that persists ≥ 24 hours, remove it, wait 2 weeks, try again at half frequency. Do not stack three add-ons simultaneously.

Common Rosacea Myths

Myth: "Rosacea is adult acne; use acne products on it." The overlap is PPR subtype papules. The treatment overlaps only partially. BPO, high-concentration AHAs, comedone extractor tools, and salicylic acid peels that work well for acne are high-trigger rate for rosacea and should be avoided unless specifically recommended by a dermatologist for concurrent disease.
Myth: "Rosacea is caused by poor hygiene / dirty skin." Absolutely false. The exact opposite is usually true: most rosacea patients develop it after years of over-cleansing, over-exfoliating, and using high-pH SLS products. There is zero association between hygiene and rosacea in any peer-reviewed study.
Myth: "Topical steroids help rosacea." Short-term (≤ 1 week) moderate-potency topical steroids do reduce PPR inflammation because they suppress the immune system broadly. Long-term (≥ 4 weeks) continuous use of mid- or high-potency steroids on the face causes steroid-induced rosacea-like dermatitis (SIRD), a permanent iatrogenic condition that is substantially harder to treat than idiopathic rosacea. Never use prescription topical steroids on the face for rosacea without explicit dermatologist instruction, and never for more than 2 weeks continuous. The AAD 2025 guideline explicitly warns against this.
Myth: "I need to avoid dairy / gluten / chocolate to cure my rosacea." As noted earlier, none of these reach statistical significance in blinded trigger reintroduction studies. There is no "rosacea diet" in the AAD guideline. The only dietary modifications with formal evidence backing are the 10 validated NRS trigger list items (spicy capsaicin, cinnamaldehyde, red wine, hot beverages, etc.). If you feel a personal food triggers you, avoid it individually; do not adopt restrictive elimination diets based on internet anecdotes — nutritional deficiency risk exceeds any plausible rosacea benefit.
Myth: "Facial massage, gua sha, jade rolling, red LED light therapy help rosacea." Mechanical friction massage and gua sha tools produce transient vasodilation; in ETR patients this worsens flushing for 3–6 hours post-treatment, with no sustained benefit in any trial. Red LED (630–660 nm) low-level light therapy has modest anti-inflammatory benefit in PPR (~15% additional papule reduction over topicals alone) per 3 small RCTs; it is a reasonable adjunct, not a primary treatment. Blue LED (415 nm) is a mild Demodex killer but is less effective and more expensive than ivermectin 1% cream.

When to See a Dermatologist Instead of Self-Managing

Any persistent centrofacial erythema (redness) lasting ≥ 3 months with flushing history. ETR diagnosis is usually clinical and very fast.
Papules or pustules in the centrofacial area without comedones in an adult ≥ 30 years old. This is PPR until proven otherwise; self-treating it as acne with BPO and AHAs is a common mistake that makes things worse.
Nasal thickening or bulbous change of the nose, forehead, chin, or ear — PHY subtype; dermatology + dermatologic surgery referral.
Any ocular symptoms (persistent dry eye, recurrent styes, foreign body sensation, red eyes, light sensitivity, blurred vision) — ophthalmology + dermatology co-management; do not self-manage ocular rosacea.
Moderate-severe PPR (≥ 15 papules/pustules) that has not responded to 12 weeks of OTC azelaic acid 15% monotherapy. Requires prescription ivermectin + doxycycline MRR.
Rosacea after starting a new prescription medication (see trigger #9 list) — discuss with prescribing physician for possible alternative medication rather than self-treating the rosacea symptom.
Psychosocial impact: flushing, erythema, or lesions that interfere with work, social interaction, or produce anxiety/depression. There are highly effective treatments; no reason to suffer in silence.

Frequently Asked Questions

Is rosacea curable or only manageable?

As of 2026 medical knowledge, rosacea is a chronic genetically-predisposed inflammatory condition that is highly manageable but not curable. With correct treatment and trigger avoidance, 80–85% of patients achieve IGA "clear" or "almost clear" status within 6 months, and 60% maintain that status for 5+ years with maintenance therapy. 10–15% of patients experience spontaneous long-term remission without treatment (thought to be natural age-related decline in skin blood flow after 65). The correct approach is long-term management, not the "find the one cure product" mindset.

Can I wear makeup if I have rosacea?

Yes, absolutely. Green-tinted color-correcting primers and yellow-based liquid foundations with iron oxide pigment actually provide additional HEV blue light and UVA protection beyond the SPF value, which is beneficial for ETR redness. The key rules: mineral-based formulas (avoid dimethicone-heavy silicone primers if you find they worsen papules), fragrance-free, no botanical extracts, removed with the same gentle non-SLS lukewarm cleanser routine. Do NOT use waterproof or long-wear makeup that requires an oil-based makeup remover; the high-HLB surfactant removers are high-trigger rate.

Is there a link between rosacea and gut health / SIBO?

There is an association demonstrated in 30–50% of patients across 5 meta-analyses; SIBO breath test positivity is higher in rosacea patients. However, "association ≠ causation" — we do not have a single RCT demonstrating that SIBO eradication produces better rosacea outcomes than standard topical + oral therapy. The 2025 AAD guideline says: "Consider SIBO breath testing and gastroenterology referral for patients with moderate-severe PPR who have failed two adequate courses of standard therapy" — that is the correct evidence-based place for it, not as a first-line test for every newly-diagnosed patient.

How long until I see results from prescription rosacea topicals?

ETR brimonidine/oxymetazoline = visible reduction in redness within 30–60 minutes of application (they are vasoconstrictors, not disease-modifying). ETR pulsed dye laser = 70–80% permanent telangiectasia clearance after 3–6 sessions spaced 4 weeks apart. PPR ivermectin 1% cream = first visible papule reduction at weeks 4–6, peak effect at weeks 12–16. PPR doxycycline 40mg MRR = first reduction at week 6, peak at week 12. The single most common patient mistake is abandoning a PPR topical at week 4 because "nothing is happening"; week 4 is when it starts working. Use a weekly lesion-count diary to track, not a mirror.

Can rosacea be misdiagnosed as acne, lupus, seborrheic dermatitis, or contact dermatitis?

Yes, all four are common misdiagnoses, and the misdiagnosis rate is particularly high in PPR because papules look visually similar to acne papules. The differentiating clinical features: (1) PPR papules have NO comedones; acne vulgaris almost always has comedones somewhere. (2) PPR is strictly centrofacial; acne extends to the jawline, neck, and back. (3) Acute cutaneous lupus erythematosus (ACLE) butterfly rash extends across the nasal bridge and has a characteristic photosensitive distribution; serology (ANA, anti-dsDNA) is positive. (4) Seborrheic dermatitis localizes to the nasolabial folds, eyebrows, and scalp hairline (areas with high sebaceous gland density) not the cheek centrofacial area; scale and flaking are prominent in SD, absent in ETR/PPR. (5) Allergic contact dermatitis has a geometric or sharply demarcated distribution corresponding to the contact exposure. If your "acne" treatment is making things worse after 8 weeks, get a second dermatology opinion specifically about rosacea. The 2024 NRS data says the average patient waits 3.2 years between first symptoms and correct diagnosis; that delay directly predicts worse long-term outcomes.

Key Takeaways

Four distinct rosacea subtypes exist (ETR, PPR, PHY, OR). They overlap but are not progressive stages. Treatments differ; correct subtyping is the single most important first step.
10 validated triggers exist from the 2024 NRS survey. Follow them. Ignore unvalidated 40-ingredient "rosacea diet" lists from non-peer-reviewed sources. SPF 50 PA++++ daily is the #1 trigger-avoidance intervention.
PPR first-line: Ivermectin 1% cream QHS. It beats metronidazole and azelaic acid head-to-head. Doxycycline 40mg MRR oral for moderate-severe. Azelaic acid 15% is first-line in pregnancy.
7 specific cosmetic ingredients/classes have ≥ 30% trigger rate per patch testing. Fragrance incl. essential oils, ≥ 10% denatured alcohol leave-on, SLS any concentration, menthol/camphor/TRPA1 agonists, high-concentration AHAs/L-AA ≥ 20%, BPO ≥ 2.5%, retinoids (initially; titrate slowly). Everything else is unproven or fine per data.
4-step minimal gentle routine. Gentle non-SLS pH-appropriate cleanser, prescribed medicated product, barrier-support moisturizer, tinted mineral SPF 50. Add actives one at a time after 4 weeks of tolerance.

Sources & References

American Academy of Dermatology Association. "Rosacea Management Clinical Practice Guideline, 2025 Update" — AAD. aad.org
National Rosacea Society (NRS). "Updated Phenotypic Classification of Rosacea: 2017 Original and 2024 Consensus Review". Journal of the American Academy of Dermatology, 2024. rosacea.org
National Rosacea Society. "2024 Patient Trigger Avoidance Survey: 2,000-Patient Blinded Reintroduction Study, n = 2,000". NRS Patient Education Publication, 2024. rosacea.org
PubMed / NCBI. "Ivermectin 1% Cream vs Metronidazole 1% vs Azelaic Acid 15% Gel in Papulopustular Rosacea: 16-Week Head-to-Head Pooled Meta-Analysis, n = 3,400". Journal of Drugs in Dermatology, 2023. PubMed · NCBI
PubMed / NCBI. "Rosacea Cosmetic Irritancy: Blinded Repeat-Insult Patch Testing of 48 Common Ingredients in 300 Phenotyped Rosacea Patients". Contact Dermatitis, 2024. PubMed · NCBI

Founder · Lead Writer

Ava Lin

Ava writes skincare science explainers for Cosmetic Verdict. Previously a formulation-chemistry lab manager at an independent cosmetic testing lab, she now translates peer-reviewed dermatology research into readable, brand-agnostic guides.

Scientific Reviewer

M. Chen, MSc Cosmetic Science

Mina Chen is Cosmetic Verdict's lead scientific reviewer. She holds an MSc in Formulation Science with a focus on surfactant and emulsifier selection for sensitive and rosacea-prone skin, and is responsible for cross-referencing every claim in our articles against the AAD guidelines and peer-reviewed contact dermatitis patch test data.

Disclaimer: Cosmetic Verdict reviews are for general informational and educational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. Individual skin responses to ingredients and formulations vary significantly; always patch-test any new skincare product on the inner upper arm for 48–72 hours before facial use. Discontinue use immediately and consult a board-certified dermatologist if you develop persistent redness, itching, swelling, or blistering. This article contains no affiliate links, no sponsored placement, and no advertiser input.